What it's for (Indications)
- Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
- This medication is a long-acting beta-3 adrenergic agonist that works by relaxing the bladder muscle.
- It is typically considered for use when other treatments, such as anticholinergic agents, are not well-tolerated or are contraindicated for a patient's specific clinical profile.
- Its mechanism provides an alternative therapeutic pathway for managing the bothersome symptoms associated with OAB, aiming to improve patient quality of life by reducing the frequency of urination, the strong, sudden urge to urinate, and episodes of involuntary urine leakage.
- The efficacy and safety profile of mirabegron have been established in various clinical trials, demonstrating its role in the contemporary management of OAB symptoms.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended starting dose for mirabegron is 25 mg taken orally once daily. Based on individual patient response and tolerability, the dose may be increased to 50 mg once daily after an initial period of 4 to 8 weeks. It is crucial for the medication to be swallowed whole with water and not chewed, crushed, or divided, as this can affect its extended-release properties. Dose adjustments are mandatory for patients with varying degrees of renal or hepatic impairment. Specifically, for individuals with severe renal impairment (creatinine clearance of 15 to 29 mL/min) or moderate hepatic impairment (Child-Pugh Class B), the maximum daily dose must not exceed 25 mg. Mirabegron is explicitly contraindicated in patients presenting with end-stage renal disease (creatinine clearance less than 15 mL/min or requiring hemodialysis) and those with severe hepatic impairment (Child-Pugh Class C) due to the risk of increased systemic exposure and potential adverse effects. Adherence to these dosage guidelines is essential to optimize efficacy and minimize risks. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with mirabegron treatment include elevations in blood pressure (hypertension), symptoms consistent with nasopharyngitis, urinary tract infections, headache, constipation, and dizziness.
- While often mild, blood pressure increases require careful monitoring, particularly in patients with a history of hypertension.
- Less common but potentially more serious adverse events that have been reported include angioedema, characterized by swelling of the face, lips, tongue, and/or larynx, which warrants immediate medical attention.
- Atrial fibrillation, a type of irregular heartbeat, has also been noted in some individuals.
- Severe hypertension requiring intervention has been observed, underscoring the importance of blood pressure management.
- Additionally, urinary retention is a recognized risk, especially in patients who have pre-existing bladder outlet obstruction or are concurrently using anticholinergic medications for overactive bladder.
- Patients should be informed about these potential side effects and advised to report any concerning symptoms to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: Mirabegron does not carry a formal FDA Black Box Warning. However, several serious warnings are crucial for patient safety and clinical management. Significant increases in blood pressure have been observed in patients treated with mirabegron, particularly those with pre-existing hypertension. It is thus contraindicated in patients with severe uncontrolled hypertension (defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg). Healthcare providers must measure blood pressure at baseline and monitor it regularly throughout treatment, especially following initiation or dose escalation. New onset or worsening hypertension requires appropriate management, including potential discontinuation of mirabegron. There is also a risk of urinary retention, primarily in patients with clinically significant bladder outlet obstruction (BOO) and those concurrently receiving antimuscarinic medications for overactive bladder. These individuals should be closely monitored for signs and symptoms of urinary retention. Additionally, cases of angioedema, involving the face, lips, tongue, and/or larynx, have been reported with mirabegron use, some occurring after the first dose. Patients experiencing such symptoms should seek immediate medical attention, as angioedema can be life-threatening. These warnings emphasize the need for careful patient selection and diligent monitoring during mirabegron therapy.
- Mirabegron therapy is associated with a risk of increased blood pressure, making it imperative to monitor blood pressure regularly, particularly in patients with known hypertension.
- It is contraindicated in patients with severe uncontrolled hypertension (defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg) to prevent exacerbation of cardiovascular risks.
- Patients should have their blood pressure assessed prior to initiating treatment and periodically thereafter, especially during dose titrations.
- Furthermore, mirabegron can precipitate or worsen urinary retention, a concern particularly for individuals with clinically significant bladder outlet obstruction (BOO) or those concurrently receiving antimuscarinic medications for overactive bladder.
- These patients require careful monitoring for any signs or symptoms of urinary retention.
- Instances of angioedema, involving the face, lips, tongue, and/or larynx, have been reported, with some cases occurring after the initial dose.
- Patients must be instructed to seek immediate medical assistance if they experience such symptoms, as angioedema can be life-threatening.
- The clinical importance of these warnings necessitates careful patient selection and ongoing vigilance during treatment.
How it Works (Mechanism of Action)
Mirabegron functions as a selective beta-3 adrenergic agonist. Its primary mechanism involves binding to and activating the beta-3 adrenergic receptors predominantly located on the detrusor smooth muscle within the urinary bladder. Activation of these receptors facilitates the relaxation of the detrusor muscle during the urine storage phase of the bladder cycle. This pharmacological action leads to an increase in the bladder's functional capacity without impairing the detrusor muscle's ability to contract during micturition (urination). Consequently, by promoting bladder relaxation, mirabegron effectively reduces the symptoms characteristic of overactive bladder, such as urinary urgency, increased urinary frequency, and urge incontinence. This distinct mechanism of action offers an alternative therapeutic approach compared to traditional anticholinergic agents, which act by blocking muscarinic receptors. The selective nature of mirabegron for beta-3 receptors minimizes off-target effects that might be associated with non-selective beta-agonists. This targeted approach enhances bladder storage function while maintaining voiding efficiency, contributing to improved symptom control for OAB patients.
Commercial Brands (Alternatives)
No other brands found for this formula.